Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism

[1] Weisberg E(2005)Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129-141

[2] Manley PW(2007)Dasatinib: a new step in molecular target therapy Ann Oncol 18 vi42-vi46

[3] Breitenstein W(2002)Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res 62 4236-4243

[4] Bruggen J(2006)Allosteric inhibitors of Bcr-abl-dependent cell proliferation Nat Chem Biol 2 95-102

[5] Cowan-Jacob SW(2010)Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 501-506

[6] Ray A(2010)Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site Biochim Biophys Acta 1804 454-462

[7] Huntly B(2008)Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl Int J Oncol 32 1197-1204

[8] Fabbro D(2012)p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia Haematologica 97 251-257

[9] Fendrich G(2000)The hallmarks of cancer Cell 100 57-70

[10] Hall-Meyers E(2010)A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-Abl J Med Chem 53 5439-5448

[1] Weisberg E(2005)Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129-141

[2] Manley PW(2007)Dasatinib: a new step in molecular target therapy Ann Oncol 18 vi42-vi46

[3] Breitenstein W(2002)Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res 62 4236-4243

[4] Bruggen J(2006)Allosteric inhibitors of Bcr-abl-dependent cell proliferation Nat Chem Biol 2 95-102

[5] Cowan-Jacob SW(2010)Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 501-506

[6] Ray A(2010)Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site Biochim Biophys Acta 1804 454-462

[7] Huntly B(2008)Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl Int J Oncol 32 1197-1204

[8] Fabbro D(2012)p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia Haematologica 97 251-257

[9] Fendrich G(2000)The hallmarks of cancer Cell 100 57-70

[10] Hall-Meyers E(2010)A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-Abl J Med Chem 53 5439-5448